Oral STC-15 for Advanced Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new oral medication, STC-15, for individuals with advanced cancer who have exhausted standard treatments or opted not to continue them. The study aims to determine the safest and most effective dose of STC-15 by exploring different dosing schedules. Participants will receive capsules in three-week cycles, and researchers will closely monitor how the body processes the drug and any effects it produces. This trial suits those with advanced cancer who have tried all available treatments and maintain good organ function. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Do I need to stop my current medications for the trial?
The trial requires that you stop any local or systemic cancer treatments at least 3 weeks before starting the study medication. Other medications are not specifically mentioned, so it's best to discuss your current medications with the trial team.
Is there any evidence suggesting that STC-15 is likely to be safe for humans?
Studies have shown that STC-15 is generally well tolerated by patients with advanced cancer. Research indicates that it does not cause severe side effects, even at varying dose levels. In previous studies, participants reported few serious adverse events, suggesting that the treatment is generally safe. Although the current trial is in its early stages and primarily focuses on safety, earlier research supports the idea that STC-15 is a promising and safe option.12345
Why do researchers think this study treatment might be promising?
Unlike the standard cancer treatments that often involve chemotherapy or radiation, STC-15 is unique because it is an oral medication, making it potentially easier and more convenient for patients to take. Researchers are excited about STC-15 because it targets cancer cells with a novel mechanism that might offer a different approach compared to existing therapies. Additionally, the varying dosing schedules being explored, such as daily or every other day, could provide options to tailor treatment to individual patient needs while potentially reducing side effects.
What evidence suggests that STC-15 might be an effective treatment for advanced cancer?
Research shows that STC-15 holds promise in treating advanced cancers. Studies have found that STC-15 is generally well tolerated, causing few side effects. It blocks an enzyme called METTL3, which aids cancer cell growth. Early results suggest this can slow or stop tumor growth in various cancers. In this trial, researchers will test STC-15 at different dose levels, with positive results seen across multiple cancer types. This makes STC-15 a hopeful option for people with advanced cancers.12456
Who Is on the Research Team?
Josefin Holz
Principal Investigator
STORM Therapeutics
Are You a Good Fit for This Trial?
Adults over 18 with advanced cancers that haven't responded to standard treatments can join this trial. They should be relatively active and have good organ function. People who've had recent major surgery, radiation, or other cancer therapies, those with autoimmune diseases needing treatment in the last 2 years, or a history of severe brain-related side effects from drugs cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive multiple ascending daily oral doses of STC-15 in 3-week treatment cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- STC-15
Find a Clinic Near You
Who Is Running the Clinical Trial?
STORM Therapeutics LTD
Lead Sponsor